Analytik Jena publishes preliminary figures
Analytik Jena AG saw a strong sales increase of 31.4% to EUR 84.5m in financial year 2002/2003 (to 30 September) (2001/2002: EUR 64.3m), according to preliminary figures.
The company's liquid funds increased considerably towards the end of the financial year, reaching EUR 6.8m (EUR 4.8m).
AJ saw a perceivable improvement in instrument demand over the last quarter of the past financial year, with analytical and bioanalytical systems sales rising by 46.8% over the third quarter of the financial year to EUR 6.5m.
Project Solutions business unit sales rose 66.3% for the entire financial year 2002/2003 from EUR 34.3m to EUR 57.1m, while instrument sales in the Analytical and Bioanalytical Solutions business units fell 9.9% to EUR 22.9m (EUR 25.4m) due to economic and currency developments. Consumer goods sales roughly matched the previous year's figures at EUR 4.4m (EUR 4.5m).
Rising from EUR 11.2m to EUR 39.9m, Europe is the company's largest regional market. German sales fell by 23% due to continued investment hesitancy, decreasing to EUR 35m for the financial year (EUR 45.5m). Exports increased to 58.5% (29.2%), thus compensating for the weak domestic market.
Analytik Jena continues to maintain a very high order backlog totaling EUR 96.2m at the end of the financial year (EUR 93.7m).
In light of the currently ongoing audit process, AJ is adhering to its previously established earnings goals. The company expects to return to positive figures, projecting a EBIT (earnings before interest and taxes of approx. EUR 0.5m to 1.0m (EUR -1.5m). Final figures for financial year 2002/2003 will be published on December 30, 2003.
Most read news
Organizations
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.